NO308798B1 - Proteinkinase-C-hemmere, anvendelse av samme for fremstilling av farmasøytika samt farmasøytisk formulering omfattende samme - Google Patents
Proteinkinase-C-hemmere, anvendelse av samme for fremstilling av farmasøytika samt farmasøytisk formulering omfattende sammeInfo
- Publication number
- NO308798B1 NO308798B1 NO944643A NO944643A NO308798B1 NO 308798 B1 NO308798 B1 NO 308798B1 NO 944643 A NO944643 A NO 944643A NO 944643 A NO944643 A NO 944643A NO 308798 B1 NO308798 B1 NO 308798B1
- Authority
- NO
- Norway
- Prior art keywords
- same
- protein kinase
- pharmaceuticals
- inhibitors
- manufacture
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229940123924 Protein kinase C inhibitor Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000003881 protein kinase C inhibitor Substances 0.000 title 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 102000003923 Protein Kinase C Human genes 0.000 abstract 1
- 108090000315 Protein Kinase C Proteins 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 150000002678 macrocyclic compounds Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
- C07C43/14—Unsaturated ethers
- C07C43/17—Unsaturated ethers containing halogen
- C07C43/174—Unsaturated ethers containing halogen containing six-membered aromatic rings
- C07C43/1745—Unsaturated ethers containing halogen containing six-membered aromatic rings having more than one ether bound
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
- C07C43/14—Unsaturated ethers
- C07C43/178—Unsaturated ethers containing hydroxy or O-metal groups
- C07C43/1785—Unsaturated ethers containing hydroxy or O-metal groups having more than one ether bound
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Indole Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16306093A | 1993-12-07 | 1993-12-07 | |
US31697394A | 1994-10-03 | 1994-10-03 |
Publications (3)
Publication Number | Publication Date |
---|---|
NO944643D0 NO944643D0 (no) | 1994-12-02 |
NO944643L NO944643L (no) | 1995-06-08 |
NO308798B1 true NO308798B1 (no) | 2000-10-30 |
Family
ID=26859318
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO944643A NO308798B1 (no) | 1993-12-07 | 1994-12-02 | Proteinkinase-C-hemmere, anvendelse av samme for fremstilling av farmasøytika samt farmasøytisk formulering omfattende samme |
Country Status (31)
Country | Link |
---|---|
US (1) | US5698578A (es) |
EP (1) | EP0657458B1 (es) |
JP (2) | JP3581731B2 (es) |
KR (1) | KR100340159B1 (es) |
CN (2) | CN1050844C (es) |
AT (1) | ATE204579T1 (es) |
AU (1) | AU687909B2 (es) |
BR (1) | BR9404831A (es) |
CA (1) | CA2137203C (es) |
CO (1) | CO4340622A1 (es) |
CY (1) | CY2413B1 (es) |
CZ (1) | CZ291950B6 (es) |
DE (1) | DE69428025T2 (es) |
DK (1) | DK0657458T3 (es) |
ES (1) | ES2162843T3 (es) |
FI (3) | FI108138B (es) |
GR (1) | GR3037087T3 (es) |
HK (1) | HK1013827A1 (es) |
HU (1) | HU219709B (es) |
IL (1) | IL111850A (es) |
MY (1) | MY125587A (es) |
NO (1) | NO308798B1 (es) |
NZ (1) | NZ270048A (es) |
PE (1) | PE49195A1 (es) |
PL (1) | PL182124B1 (es) |
PT (1) | PT657458E (es) |
RU (1) | RU2147304C1 (es) |
SG (1) | SG63570A1 (es) |
TW (1) | TW425397B (es) |
UA (1) | UA44690C2 (es) |
YU (1) | YU49200B (es) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5723456A (en) * | 1993-12-07 | 1998-03-03 | Eli Lilly & Company | Therapeutic treatment for cardiovascular diseases |
US5624949A (en) * | 1993-12-07 | 1997-04-29 | Eli Lilly And Company | Protein kinase C inhibitors |
AU701659B2 (en) | 1995-11-20 | 1999-02-04 | Eli Lilly And Company | Novel intermediates and their use to prepare n,n'-bridged bisindolylmaleimides |
UA61897C2 (en) * | 1995-11-20 | 2003-12-15 | Lilly Co Eli | Protein kinase c inhibitors, methods for synthesis, pharmaceutical formulations and methods for treating microvascular diabetic complications |
WO1997034890A1 (en) * | 1996-03-20 | 1997-09-25 | Eli Lilly And Company | Synthesis of indolylmaleimides |
UA54427C2 (uk) * | 1996-05-01 | 2003-03-17 | Елі Ліллі Енд Компані | Спосіб лікування очних захворювань, які пов'язані з фактором васкулярного ендотеліального росту |
WO1997040830A1 (en) | 1996-05-01 | 1997-11-06 | Eli Lilly And Company | Therapeutic treatment for vegf related diseases |
PL329681A1 (en) * | 1996-05-01 | 1999-04-12 | Lilly Co Eli | Halogen-substituted inhibitor of proteinous kinase c |
US6093709A (en) * | 1996-08-22 | 2000-07-25 | Eli Lilly And Company | Therapeutic treatment for sexual dysfunctions |
US5962446A (en) * | 1996-08-30 | 1999-10-05 | Eli Lilly And Company | Therapetutic treatment for human T cell lymphotrophic virus type 1 infection |
AU4250697A (en) * | 1996-08-30 | 1998-03-19 | Eli Lilly And Company | Use of inhibitors of pkc for the manufacture of a medicament for the treatment of central nervous system diseases associated with hiv infection |
PL331761A1 (en) * | 1996-08-30 | 1999-08-02 | Lilly Co Eli | Application of pkc inhibitors in production of a drug for treating central nervous system diseases associated with hiv infections |
US6107327A (en) * | 1996-08-30 | 2000-08-22 | Eli Lilly And Company | Therapeutic treatment for HIV infection |
US5721272A (en) * | 1996-11-18 | 1998-02-24 | Eli Lilly And Company | Intermediates and their use to prepare N,N'-bridged bisindolylmaleimides |
US6093740A (en) * | 1997-04-30 | 2000-07-25 | Eli Lilly And Company | Therapeutic treatment for skin disorders |
JPH1135454A (ja) * | 1997-07-22 | 1999-02-09 | Meiji Milk Prod Co Ltd | 抗腫瘍剤 |
JP3646651B2 (ja) * | 1998-01-30 | 2005-05-11 | ダイソー株式会社 | ブタントリオール誘導体の製造法 |
US6225301B1 (en) | 1998-03-05 | 2001-05-01 | Eli Lilly And Company | Therapeutic treatment for renal dysfunction |
US6291446B1 (en) | 1998-03-05 | 2001-09-18 | Eli Lilly And Company | Therapeutic treatment for cytomegalovirus infection |
US6103713A (en) * | 1998-03-05 | 2000-08-15 | Eli Lilly And Company | Therapeutic treatment for autoimmune diseases |
US6103712A (en) * | 1998-03-05 | 2000-08-15 | Eli Lilly And Company | Therapeutic treatment for asthma |
AU758241B2 (en) * | 1998-03-13 | 2003-03-20 | University Of British Columbia, The | Granulatimide derivatives for use in cancer treatment |
CA2245029A1 (en) | 1998-03-13 | 1999-09-13 | University Of British Columbia | Granulatimide compounds as g2 checkpoint inhibitors |
US6127401A (en) | 1998-06-05 | 2000-10-03 | Cephalon, Inc. | Bridged indenopyrrolocarbazoles |
US6492406B1 (en) * | 1999-05-21 | 2002-12-10 | Astrazeneca Ab | Pharmaceutically active compounds |
ES2245994T3 (es) * | 2000-12-08 | 2006-02-01 | Ortho-Mcneil Pharmaceutical, Inc. | Compuestos macro-heterociclicos utilizados como inhibidores de quinasa. |
DE10109280A1 (de) * | 2001-02-26 | 2002-09-05 | Peter Mayser | Indolderivate mit inhibitorischer Wirkung auf Proteinkinasen |
US20030119812A1 (en) * | 2001-11-08 | 2003-06-26 | Brazzell Romulus Kimbro | Method for decreasing capillary permeability in the retina |
DE60217918T2 (de) * | 2001-12-29 | 2007-11-15 | Novo Nordisk A/S | Kombinierte verwendung einer glp-1-verbindung und eines aldose reduktase inhibitors |
US6887864B2 (en) | 2002-03-12 | 2005-05-03 | Hoffmann-La Roche Inc. | Azepane derivatives |
US20030236246A1 (en) * | 2002-04-30 | 2003-12-25 | Brazzell Romulus Kimbro | Method for decreasing capillary permeability in the retina |
DE10233737A1 (de) * | 2002-07-24 | 2004-02-05 | Morphochem Aktiengesellschaft für kombinatorische Chemie | Verwendung von Modulatoren des Signaltransduktionswegs über die Proteinkinase Fyn zur Behandlung von Tumorerkrankungen |
ATE457995T1 (de) | 2003-06-18 | 2010-03-15 | Tranzyme Pharma Inc | Makrozyklische motilin rezeptorantagonisten |
CA2533861A1 (en) | 2003-08-08 | 2005-02-17 | Novartis Ag | Combinations comprising staurosporines |
NZ550340A (en) * | 2004-03-17 | 2010-08-27 | Lars Michael Larsen | Prevention of retinopathy by inhibition of the visual cycle using a retinoid |
JO3088B1 (ar) * | 2004-12-08 | 2017-03-15 | Janssen Pharmaceutica Nv | مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف |
US8158586B2 (en) * | 2005-04-11 | 2012-04-17 | Pharmagap Inc. | Inhibitors of protein kinases and uses thereof |
CA2645289A1 (en) | 2006-03-10 | 2007-09-20 | Janssen Pharmaceutica, N.V. | Pyridine-containing macroheterocylic compounds as kinase inhibitors |
EP2181999A1 (en) | 2008-11-03 | 2010-05-05 | Zentiva, A.S. | Method of manufacturing ruboxistarin |
ES2385157B1 (es) * | 2010-02-25 | 2013-07-08 | Universidad Del País Vasco | Compuestos para el tratamiento de alzheimer. |
CA2795456A1 (en) | 2010-03-30 | 2011-10-06 | Novartis Ag | Pkc inhibitors for the treatment of b-cell lymphoma having chronic active b-cell-receptor signalling |
US8785648B1 (en) | 2010-08-10 | 2014-07-22 | The Regents Of The University Of California | PKC-epsilon inhibitors |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
US8846712B2 (en) | 2011-09-12 | 2014-09-30 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2847191B1 (en) | 2012-05-09 | 2016-06-15 | Sanofi | Substituted 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine derivatives as kinase inhibitors |
RU2674995C2 (ru) | 2012-11-29 | 2018-12-14 | Новартис Аг | Фармацевтические комбинации |
WO2014174478A1 (en) | 2013-04-26 | 2014-10-30 | Novartis Ag | Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor |
EP3180003B1 (en) | 2014-07-01 | 2022-01-12 | The Regents of the University of California | Pkc-epsilon inhibitors |
JO3589B1 (ar) | 2014-08-06 | 2020-07-05 | Novartis Ag | مثبطات كيناز البروتين c وطرق استخداماتها |
AU2016287568B2 (en) | 2015-07-02 | 2020-08-20 | Turning Point Therapeutics, Inc. | Chiral diaryl macrocycles as modulators of protein kinases |
US20180325901A1 (en) * | 2015-07-21 | 2018-11-15 | Tp Therapeutics, Inc. | Chiral diaryl macrocycles and uses thereof |
CN106854141A (zh) * | 2015-12-08 | 2017-06-16 | 湖南华腾制药有限公司 | 一种4-氯甲苯化合物的合成方法 |
CN107778148A (zh) * | 2016-08-30 | 2018-03-09 | 湖南华腾制药有限公司 | 一种溴化苄衍生物的合成方法 |
TWI808958B (zh) | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
WO2018175340A1 (en) | 2017-03-20 | 2018-09-27 | Sienna Biopharmaceuticals, Inc. | Reduced exposure conjugates modulating therapeutic targets |
WO2018175302A1 (en) | 2017-03-20 | 2018-09-27 | Sienna Biopharmaceuticals, Inc. | Polymer conjugates targeting c-src with reduced exposure |
AU2018306328B2 (en) | 2017-07-28 | 2023-03-09 | Turning Point Therapeutics, Inc. | Macrocyclic compounds and uses thereof |
BR112020012319A2 (pt) | 2017-12-19 | 2020-11-24 | Turning Point Therapeutics, Inc. | compostos macrocíclicos para tratar doença |
EP4201403A1 (en) | 2021-12-21 | 2023-06-28 | Som Innovation Biotech, S.L. | Compounds tirapazamine and quazinone for use in the treatment of gm2 gangliosidoses |
US20230203017A1 (en) * | 2021-12-28 | 2023-06-29 | Kamal D. Mehta | Protein Kinase C Beta Inhibitors and Uses Thereof |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4808613A (en) * | 1986-11-21 | 1989-02-28 | Bristol-Myers Company | Rebeccamycin derivative containing pharmaceutical composition |
US4785085A (en) * | 1986-11-21 | 1988-11-15 | Bristol-Myers Company | Rebeccamycin analogs |
EP0303697B1 (en) * | 1987-03-09 | 1997-10-01 | Kyowa Hakko Kogyo Co., Ltd. | Derivatives of physiologically active substance k-252 |
US5438050A (en) * | 1988-02-06 | 1995-08-01 | Godecke Aktiengesellschaft | Indolocarbazole derivatives, processes for their preparation and compositions containing them |
DE3803620A1 (de) * | 1988-02-06 | 1989-08-17 | Goedecke Ag | Indolocarbazol-derivate, verfahren zu deren herstellung und diese enthaltende arzneimittel |
SK75289A3 (en) * | 1988-02-10 | 1998-05-06 | Hoffmann La Roche | Substituted pyrroles, their use for producing a drug, and the drug on their base |
MC2096A1 (fr) * | 1989-02-23 | 1991-02-15 | Hoffmann La Roche | Pyrroles substitues |
US5380746A (en) * | 1989-05-05 | 1995-01-10 | Goedecke Aktiengesellschaft | Bis-(1H-indol-3-YL)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them |
DE3914764A1 (de) * | 1989-05-05 | 1990-11-08 | Goedecke Ag | Maleinimid-derivate und deren verwendung als arzneimittel |
IL94274A0 (en) * | 1989-05-05 | 1991-03-10 | Goedecke Ag | Maleinimide derivatives,process for the preparation thereof and pharmaceutical compositions containing the same |
DE3924538A1 (de) * | 1989-07-25 | 1991-01-31 | Goedecke Ag | Indolocarbazol und dessen verwendung |
DE3942296A1 (de) * | 1989-12-21 | 1991-06-27 | Goedecke Ag | Indolocarbazol-derivate, verfahren zu deren herstellung und deren verwendung |
DE4005970A1 (de) * | 1990-02-26 | 1991-08-29 | Boehringer Mannheim Gmbh | Neue trisubstituierte maleinimide, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten |
DE4005969A1 (de) * | 1990-02-26 | 1991-08-29 | Boehringer Mannheim Gmbh | Neue trisubstituierte pyrrole, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten |
CA2046801C (en) * | 1990-08-07 | 2002-02-26 | Peter D. Davis | Substituted pyrroles |
US5292747A (en) * | 1990-08-07 | 1994-03-08 | Hoffman-La Roche Inc. | Substituted pyrroles |
JPH04187686A (ja) * | 1990-11-20 | 1992-07-06 | Meiji Seika Kaisha Ltd | インドロカルバゾール誘導体 |
EP0508792A1 (en) * | 1991-04-11 | 1992-10-14 | Schering Corporation | Anti-tumor and anti-psoriatic agents |
GB9123396D0 (en) * | 1991-11-04 | 1991-12-18 | Hoffmann La Roche | A process for the manufacture of substituted maleimides |
US5461146A (en) * | 1992-07-24 | 1995-10-24 | Cephalon, Inc. | Selected protein kinase inhibitors for the treatment of neurological disorders |
US5589472A (en) * | 1992-09-25 | 1996-12-31 | Vice; Susan F. | Diindolo compounds and pharmaceutical compositions containing them |
DE4243321A1 (de) * | 1992-12-21 | 1994-06-23 | Goedecke Ag | Aminosäurederivate von Heterocyclen als PKC-Inhibitoren |
AU678435B2 (en) * | 1993-05-10 | 1997-05-29 | F. Hoffmann-La Roche Ag | Substituted pyrroles |
US5624949A (en) * | 1993-12-07 | 1997-04-29 | Eli Lilly And Company | Protein kinase C inhibitors |
-
1994
- 1994-12-02 JP JP29939994A patent/JP3581731B2/ja not_active Expired - Fee Related
- 1994-12-02 HU HU9403468A patent/HU219709B/hu not_active IP Right Cessation
- 1994-12-02 NZ NZ270048A patent/NZ270048A/en not_active IP Right Cessation
- 1994-12-02 ES ES94308947T patent/ES2162843T3/es not_active Expired - Lifetime
- 1994-12-02 PE PE1994256342A patent/PE49195A1/es not_active Application Discontinuation
- 1994-12-02 AT AT94308947T patent/ATE204579T1/de active
- 1994-12-02 CN CN94119362A patent/CN1050844C/zh not_active Expired - Fee Related
- 1994-12-02 AU AU79188/94A patent/AU687909B2/en not_active Ceased
- 1994-12-02 BR BR9404831A patent/BR9404831A/pt not_active Application Discontinuation
- 1994-12-02 UA UA94129116A patent/UA44690C2/uk unknown
- 1994-12-02 CA CA002137203A patent/CA2137203C/en not_active Expired - Fee Related
- 1994-12-02 PL PL94306084A patent/PL182124B1/pl not_active IP Right Cessation
- 1994-12-02 RU RU94042922A patent/RU2147304C1/ru not_active IP Right Cessation
- 1994-12-02 KR KR1019940032547A patent/KR100340159B1/ko not_active IP Right Cessation
- 1994-12-02 DE DE69428025T patent/DE69428025T2/de not_active Expired - Lifetime
- 1994-12-02 DK DK94308947T patent/DK0657458T3/da active
- 1994-12-02 IL IL11185094A patent/IL111850A/en not_active IP Right Cessation
- 1994-12-02 TW TW083111226A patent/TW425397B/zh not_active IP Right Cessation
- 1994-12-02 CZ CZ19943018A patent/CZ291950B6/cs not_active IP Right Cessation
- 1994-12-02 SG SG1996003093A patent/SG63570A1/en unknown
- 1994-12-02 EP EP94308947A patent/EP0657458B1/en not_active Expired - Lifetime
- 1994-12-02 YU YU70494A patent/YU49200B/sh unknown
- 1994-12-02 NO NO944643A patent/NO308798B1/no not_active IP Right Cessation
- 1994-12-02 PT PT94308947T patent/PT657458E/pt unknown
- 1994-12-02 FI FI945706A patent/FI108138B/fi not_active IP Right Cessation
- 1994-12-05 CO CO94055192A patent/CO4340622A1/es unknown
- 1994-12-05 MY MYPI94003239A patent/MY125587A/en unknown
-
1996
- 1996-10-21 US US08/734,292 patent/US5698578A/en not_active Expired - Lifetime
-
1997
- 1997-12-09 CN CN97126094A patent/CN1055089C/zh not_active Expired - Fee Related
-
1998
- 1998-12-23 HK HK98115199A patent/HK1013827A1/xx not_active IP Right Cessation
-
2000
- 2000-03-07 FI FI20000516A patent/FI20000516A/fi unknown
-
2001
- 2001-05-28 FI FI20011109A patent/FI20011109A/fi unknown
- 2001-10-30 CY CY0100035A patent/CY2413B1/xx unknown
- 2001-10-31 GR GR20010401960T patent/GR3037087T3/el unknown
-
2004
- 2004-05-25 JP JP2004154808A patent/JP2004269543A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO308798B1 (no) | Proteinkinase-C-hemmere, anvendelse av samme for fremstilling av farmasøytika samt farmasøytisk formulering omfattende samme | |
CA2216535A1 (en) | Protein kinase c inhibitors | |
MY118068A (en) | Protein kinase c inhibitor | |
ATE215954T1 (de) | Pyrazolo(4,3-d)pyrimidin-derivate und diese enthaltende pharmazeutische zubereitungen | |
GEP20063784B (en) | Optical Resolution of (1-Benzyl-4- Methylpiperidin-3-Yl) -Methylamine Enantiomers and Use Thereof for Preparation of Pyrrolo 2,3-Pyrimidine Derivatives as Protein Kinases Inhibitors | |
ATE79619T1 (de) | Arzneimittel. | |
NO305903B1 (no) | Benzonitriler og benzofluorider, legemidler bestående av forbindelsene, farmasöytiske preparater inneholdende forbindelsene, samt anvendelse av forbindelsene for fremstilling av farmasöytiske preparater | |
NO933524D0 (no) | Krystallisk tiagabinhydrokloridmonohydrat samt fremstilling og anvendelse derav | |
NO304738B1 (no) | Acylerte aminoalkanimidazoler og -triazoler, farmasoeytisk preparat inneholdende disse samt anvendelse av for bindelsene for fremstilling av farmasoeytiske preparater | |
DK0916670T3 (da) | Pyrrolo[3,2-b]pyridiner og deres anvendelse som 5-HT1f-agonister | |
EA199800368A1 (ru) | Новые промежуточные продукты и их использование для получения n,n'-мостиковых бисиндолилмалеимидов |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |